Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea-Reference-Cited by-同舟云学术

Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea

Published:2022-08-08 Issue:1 Volume:11 Page:12-19
ISSN:2155-6660
Container-title:Journal of Drug Assessment
language:en
Short-container-title:Journal of Drug Assessment

Author:

Novick Diego¹,Lee Sae Young²,Koo Dong Hyun²,Szende Agota³^ORCID,Colman Sam⁴^ORCID

Affiliation:

1. GPORWE International, Eli Lilly and Company, Windlesham, Surrey, UK

2. Medical Department, Eli Lilly and Company Korea, Seoul, Korea

3. Covance Market Access Services, Labcorp Clinical Development Limited, Leeds, UK

4. Covance Market Access Services, Labcorp Clinical Development Limited, Sydney, Australia

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/21556660.2022.2107834

Reference25 articles.

1. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015

2. Korea Central Cancer Registry and National Cancer Center. Annual report of cancer statistics in Korea in 2015. http://ncc.re.kr/downloadByFileUrl.ncc?path=/downloadFiles/eng/Annual2017.

3. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers

4. NCCN. NCCN Clinical practice guidelines in oncology: Breast Cancer. Version 1.2018 – March 20, 2018.

5. Palbociclib and Letrozole in Advanced Breast Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients;Current Medical Research and Opinion;2024-05-09

2. Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in a Real-World Setting in Taiwan;Value in Health Regional Issues;2023-07

3. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review;Targeted Oncology;2023-04-19